A report from EIU healthcare

Time to Act Now for Prediabetes: The Economic Burden in Six Emerging Markets

EIU Healthcare, commissioned by Merck KGaA, has conducted a research programme to illuminate the costs of inaction around prediabetes, as well as the potential economic impact of delaying the onset of type 2 diabetes by intervening across a selection of six emerging markets (Brazil, China, Indonesia, Mexico, Russia and Saudi Arabia).

Download free report and data model

By 2045, more than 700 million adults are expected to have diabetes globally, costing more than US$ 845 billion according to the International Diabetes Federation. Given these risks and the often-asymptomatic nature of prediabetes, there is an increasing need to better understand the epidemiological and economic burden for more effective policy and action, particularly in emerging markets.

Download 2021 webinar and summary

This webinar recorded on 25th March 2021 takes an in-depth look at the potential impact and benefits of direct action on prediabetes. The discussion was based around the report “Time to Act Now for Prediabetes: The Economic Burden in Six Emerging Markets” and the need to better understand how to develop more effective policy and action for this neglected condition.

Dr Rob Cook talks with Niti Pall, KPMG Global Healthcare Practice; Michele Cecchini, Senior Economist of Healthcare Policy and Research, OECD; Kim Green, Director of Primary Health care at PATH (Program for Appropriate Technology in Health); and Elsa Morandat, Program Manager, World Diabetes Foundation.

Healthcare consultancy

We help healthcare organisations to build and maintain successful and sustainable business.Together with our two specialised consultancies, Bazian and Clearstate, EIU Healthcare provides customised research, analysis and recommendations across the healthcare ecosystem.